ALPINE, UT, Nov. 8 /PRNewswire-FirstCall/ -- American Biotech Labs (ABL), a private company (Clifton Mining Company owns 23% of ABL) is pleased to announce that a peer review study has just been published. The study shows that adding ABL silver to antibiotics improves their efficacy. THE PEER REVIEWED STUDY ----------------------- The new study was just released in Current Science (VOL.91 NO. 7, 10 October P.026) a prestigious international scientific journal. The study was authored by scientists from Viridis Biopharma and a leading US university. In the study 19 different antibiotics were tested in vitro against seven pathogens, including resistant superbugs. ABL's silver was then added to the antibiotics. In nearly all of the tests the silver was found to be either synergistic or additive with the antibiotics. THE SIGNIFICANCE OF THESE RESULTS --------------------------------- Keith Moeller, a managing director of ABL, said, "What this means is that we may have discovered a way to make existing antibiotics more effective, even against resistant bacteria. By adding our silver to antibiotics we may be able to overcome antibiotic resistance. This could increase the life span and efficacy of individual antibiotics and positively impact millions of people." A copy of the study can be found on the web at: http://www.iisc.ernet.in/currsci/oct102006/926.pdf Clifton trades on the U.S. OTC: (CFTN). Note: Any statements released by Clifton Mining Company that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward looking statements invoke risk and uncertainties that may affect the company's business prospects and performance. DATASOURCE: Clifton Mining Company CONTACT: Dr. Ken Friedman, President at (303) 642-0659, Keith Moeller, Vice President at (801) 756-1414 or see our website at http://www.cliftonmining.com/ or American Biotech Labs at http://www.americanbiotechlabs.com/

Copyright